Patent 11242343 was granted and assigned to Incyte on February, 2022 by the United States Patent and Trademark Office.
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.